Amplia Therapeutics

Amplia Therapeutics Limited is an Australian pharmaceutical company dedicated to developing focal adhesion kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer immunology, with Amplia having a particular development focus on pancreatic and ovarian cancers. FAK also plays a significant role in many chronic diseases, such as idiopathic pulmonary fibrosis (IPF).